西姆拉诺德,第二代氧化物捐赠者,心力衰竭与减少喷射分数:血液动力学效率和安全性概况的元分析
Mrunalini Dandamudi1, Vinh Q T Ho2, Miguel A Samaniego-Laguna3
1Montefiore Einstein Medical Center, 111 E 210th St, Bronx, NY, 10467, USA. mdandamudi@montefiore.org.
概括
齐姆拉诺德并没有改善心脏衰竭的死亡率或关键指标,在减少喷射率的患者中. 该药物增加了症状性低血压的风险,这表明目前不建议常规使用.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学 是一个学科.
背景情况:
- 心力衰竭 (HF) 是一个重大的全球健康挑战.
- 氧化 (HNO) 捐赠者,如Cimlanod,由于血管扩张性质,显示出HF治疗的潜力.
研究的目的:
- 评估Cimlanod在心力衰竭患者的安全性,耐受性和血液动力学影响.
主要方法:
- 这是一项对4项涉及459名患者的研究的元分析,其中包括278名西姆拉诺德患者和181名安慰剂患者.
- 评估结果包括死亡率,不良事件和血液动力学测量.
- 使用Cochrane方法评估研究质量;协议注册在PROSPERO.
主要成果:
- 与安慰剂相比,西姆拉诺德并没有显著降低全因死亡率,心脏病死亡率或不良事件.
- 观察到症状性低血压风险显著增加 (RR=2.22).
- 在最高的Cimlanod剂量下,系统血压显著下降.
结论:
- 在HFrEF患者中,Cimlanod没有在改善死亡率或主要血液动力学终点方面表现出有效性.
- 该药物增加了症状性低血压的风险.
- 目前的证据不支持常规使用Cimlanod;需要对特定子组进行进一步研究.
相关概念视频
Heart Failure II: Pathophysiology
1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure
4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction
958
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
958
Heart Failure VI: Adjunct Therapies
399
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
399
Heart Failure Drugs: Diuretics
1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management
363
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
363


